Novitium’s Pyridostigmine Shows Six Appeal Of CGT Pathway

 
• By Aidan Fry

In granting its sixth approval for an ANDA with a Competitive Generic Therapy (CGT) designation, the FDA insists it is fostering competition in the US off-patent market.

Eggs
US approvals under the newly created Competitive Generic Therapy (CGT) scheme have now hit the half-dozen mark • Source: Shutterstock

Novitium Pharma is the recipient of the sixth generic drug approval granted by the US Food and Drug Administration (FDA) with a Competitive Generic Therapy (CGT) designation under a regulatory pathway aimed at encouraging generic market entry for “drugs with inadequate competition”.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Products

More from Generics Bulletin